TY  - JOUR

T1  - Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

JO  - PharmacoEconomics

UR  - https://eprints.whiterose.ac.uk/id/eprint/116243

UR  - https://doi.org/10.1007/s40273-016-0386-z

PY  - 2016/07/01

AU  - Squires H

AU  - Stevenson M

AU  - Simpson E

AU  - Harvey R

AU  - Stevens J

ED  - 

DO  - DOI: 10.1007/s40273-016-0386-z

PB  - Springer Verlag 

VL  - 34

IS  - 7

SP  - 673

EP  - 680

Y2  - 2024/12/26

ER  -